Advertisement

Serum paraoxonase-1 activity in Helicobacter pylori infected subjects

      Abstract

      Previous studies have suggested that Helicobacter pylori (H. pylori) infection may play an important role in the process of atherosclerosis. The objective of this study was to investigate serum paraoxonase and arylesterase activities, and lipid hydroperoxide (LOOH) and total thiol (SH) levels along with lipid parameters in H. pylori infected subjects. Fifty-six H. pylori positive subjects and 43 H. pylori negative subjects were enrolled. Serum paraoxonase and arylesterase activities were measured spectrophotometrically. LOOH levels were measured by FOX-2 assay. Serum SH levels, paraoxonase and arylesterase activities were significantly lower in H. pylori positive group than H. pylori negative group (all p < 0.05), while LOOH levels were significantly higher (p < 0.05). In H. pylori positive subjects, serum LOOH levels were correlated with SH levels (r = −0.247, p < 0.05), serum paraoxonase (r = −0.432, p < 0.05) and arylesterase activities (r = −0.404, p < 0.001), and triglyceride (r = 0.305, p < 0.05), total cholesterol (r = 0.568, p < 0.05), high-density lipoprotein-cholesterol (HDL-C) (r = −0.300, p < 0.05) and low-density lipoprotein-cholesterol (LDL-C) (r = 0.577, p < 0.05) levels. Serum paraoxonase and arylesterase activities were also correlated with HDL-C levels (r = 0.221, p < 0.05 and r = 0.291, p < 0.05, respectively), while no correlation was observed with triglyceride, total cholesterol and LDL-C levels (both p > 0.05). In conclusion, paraoxonase and arylesterase activities decrease significantly in H. pylori infected subjects. Lower serum paraoxonase-1 (PON1) activity seems to be related to decrease in HDL-C and, in part, to increased oxidative stress and inflammatory condition induced by H. pylori infection. Measurement of serum PON1 activity may help in the early identification of H. pylori infected subjects with increased risk of atherosclerotic disease.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Misiewicz J.J.
        Current insights in the pathogenesis of Helicobacter pylori infection.
        Eur J Gastroenterol Hepatol. 1995; 7: 701-703
        • Leontiadis G.I.
        • Sharma V.K.
        • Howden C.W.
        Non-gastrointestinal tract associations of Helicobacter pylori infection.
        Arch Intern Med. 1999; 159: 925-940
        • Moller De
        • Flier J.S.
        Insulin resistance—mechanisms, syndromes, and implications.
        N Engl J Med. 1991; 325: 938-948
        • Ross R.
        The pathogenesis of atherosclerosis: a perspective for the 1990s.
        Nature. 1993; 632: 801-809
        • Epstein S.
        • Zhou Y.F.
        • Zhu J.
        Infection and atherosclerosis: emerging mechanistic paradigms.
        Circulation. 1999; 100: 20-28
        • Niemela S.
        • Karttunen T.
        • Korhonen T.
        • et al.
        Could Helicobacter pylori infection increase the risk of coronary heart disease by modifying serum lipid concentrations?.
        Heart. 1996; 75: 573-575
        • Hoffmeister A.
        • Rothenbacher D.
        • Bode G.
        • et al.
        Current infection with Helicobacter pylori, but not seropositivity to Chlamydia pneumoniae or cytomegalovirus, is associated with an atherogenic, modified lipid profile.
        Arterioscler Thromb Vasc Biol. 2001; 21: 427-432
        • Witzum J.L.
        • Steinberg D.
        Role of oxidized low density lipoprotein in atherogenesis.
        J Clin Invest. 1991; 88: 1785-1792
        • Canales A.
        • Sanchez-Muniz F.J.
        Paraoxanase something more than an enzyme?.
        Med Clin (Barc). 2003; 121: 537-548
        • Mackness M.I.
        • Abbott C.
        • Arrol S.
        • Durrington P.N.
        The role of high density lipoprotein and lipid-soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation.
        Biochem J. 1993; 294: 829-834
        • Parthasarathy S.
        • Barnett J.
        • Fong L.G.
        High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein.
        Biochim Biophys Acta. 1990; 1044: 275-283
        • Dixon M.F.
        • Genta R.M.
        • Yardley J.H.
        • Correa P.
        Classification and grading of gastritis. The updated System of Sydney.
        Am J Surg Pathol. 1996; 20: 1161-1181
        • Sodergren E.
        • Nourooz-Zadeh J.
        • Berglund L.
        • Vessby B.
        Re-evaluation of the ferrous oxidation in xylenol orange assay for the measurement of plasma lipid hydroperoxides.
        J Biochem Biophys Methods. 1998; 37: 137-146
        • Eckerson H.W.
        • Wyte M.C.
        • La Du B.N.
        The human serum paraoxonase/arylesterase polymorphism.
        Am J Hum Genet. 1983; 35: 1126-1138
        • Haagen L.
        • Brock A.
        A new automated method for phenotyping arylesterase (E.C. 3.1.1.2) based upon inhibition of enzymatic hydrolysis of 4-nitrophenyl acetate by phenyl acetate.
        Eur J Clin Chem Clim Biochem. 1992; 30: 391-395
        • Nourooz Zadeh J.
        Ferrous ion oxidation in presence of xylenol orange for detection of lipid hydroperoxides in plasma.
        Methods Enzymol. 1999; 300: 58-62
        • Hu M.L.
        • Louie S.
        • Cross C.E.
        • Motchnik P.
        • Halliwell B.
        Antioxidant protection against hypochlorous acid in human plasma.
        J Lab Clin Med. 1993; 121: 257-262
        • Stocker R.
        • Keaney Jr., J.F.
        Role of oxidative modifications in atherosclerosis.
        Physiol Rev. 2004; 84: 1381-1478
        • Mackness M.I.
        • Durrington P.N.
        High-density lipoprotein, its enzymes and its potential to influence lipid peroxidation.
        Atherosclerosis. 1995; 115: 243-253
        • Watson A.D.
        • Berliner J.A.
        • Hama S.Y.
        • et al.
        Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low-density lipoprotein.
        J Clin Invest. 1995; 96: 2882-2891
        • Aydemir S.
        • Bayraktaroglu T.
        • Sert M.
        • et al.
        The effect of Helicobacter pylori insulin resistance.
        Dig Dis Sci. 2005; 50: 2090-2093
        • Asahi M.
        • Azuma T.
        • Ito S.
        • et al.
        Helicobacter pylori CagA protein can be tyrosine phosphorylated in gastric epithelial cells.
        J Exp Med. 2000; 191: 593-602
        • Khanzode S.S.
        • Khanzode S.D.
        • Dakhale G.N.
        Serum and plasma concentration of oxidant and antioxidants in patients of Helicobacter pylori gastritis and its correlation with gastric cancer.
        Cancer Lett. 2003; 195: 27-31
        • Aslan M.
        • Nazligul Y.
        • Horoz M.
        • et al.
        Serum prolidase activity and oxidative status in Helicobacter pylori infection.
        Clin Biochem. 2007; 40: 37-40
        • Rodriguez-Porcel M.
        • Lerman L.O.
        • Herrmann J.
        • Sawamura T.
        • Napoli C.
        • Lerman A.
        Hypercholesterolemia and hypertension have synergistic deleterious effects on coronary endothelial function.
        Arterioscler Thromb Vasc Biol. 2003; 23: 885-891
        • Endo K.
        • Miyashita Y.
        • Sasaki H.
        • et al.
        Probucol and atorvastatin decrease urinary 8-hydroxy-2′-deoxyguanosine in patients with diabetes and hypercholesterolemia.
        J Atheroscler Thromb. 2006; 13: 68-75
        • Dirican M.
        • Akca R.
        • Sarandol E.
        • Dilek K.
        Serum paraoxonase activity in uremic predialysis and hemodialysis patients.
        J Nephrol. 2004; 17: 813-818
        • Kanbay M.
        • Gur G.
        • Yucel M.
        • Yilmaz U.
        • Boyacioglu S.
        Does eradication of Helicobacter pylori infection help normalize serum lipid and CRP levels?.
        Dig Dis Sci. 2005; 50: 1228-1231
        • Aviram M.
        • Rosenblat M.
        • Billecke S.
        • et al.
        Human serum paraoxonase (PON1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants.
        Free Radical Biol Med. 1999; 26: 892-904
        • Karakucuk S.
        • Baskol G.
        • Oner A.O.
        • Baskol M.
        • Mirza E.
        • Ustdal M.
        Serum paraoxonase activity is decreased in the active stage of Behcet's disease.
        Br J Ophthalmol. 2004; 88: 1256-1258
        • Baskol G.
        • Baskol M.
        • Yurci A.
        • Ozbakir O.
        • Yucesoy M.
        Serum paraoxonase-1 activity and malondialdehyde levels in patients with ulcerative colitis.
        Cell Biochem Funct. 2006; 24: 283-286